Tuberculosis: guidelines changed for latent TB treatment.
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002487:Centers for Disease Control and Prevention, U.S.; D004359:Drug Therapy, Combination; D006801:Humans; D017410:Practice Guidelines as Topic; D011718:Pyrazinamide / Q000008:administration & dosage / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy*; D014481:United States
D000995:Antitubercular Agents; D011718:Pyrazinamide; D012293:Rifampin